Monday 30 March 2009
(Hosted by Fasken Martineau)
(Sponsored by :RSA)
(Organised by: Asia-Pacific Technology Network)
Chair
Speakers
- Ian Boulton, TropMed Pharma Consulting (Former Director, Global Commercial Strategy, Diseases
of the Developing World, GlaxoSmithKline)
- "Reflections on an Asian-oriented career"
- Ian Price, former Regional Vice President – Far East/Australasia/S.Africa, Schering-Plough
- Nick Stephens, Chief Executive Officer RSA
- "Skills challenges and opportunities for companies and for people"
Location: Fasken Martineau, 17 Hanover Square London W1S 1HU
Nearest tube station: Oxford Circus
Timing: Registration from 5pm: Seminar starts at 5.30 pm: drinks from around 7.15 pm.
Pricing:
- Free to Fasken Martineau clients and APTN annual subscribers
- £40 + VAT (Executives)
- £20 + VAT (Asian citizens/institutions, officials, executives from Small Companies)
- £10 + VAT (Academics),
- Free for the Media.
To Register your interest: please send your details (name, institutional affiliation, email address, phone number) to biz@aptn.org
Background
- This seminar will look at career development and the Asian pharma industry, asking questions about how the roles of Asian and "Western" executives have evolved over time. Nick will be talking from his perspective as an executive recruiter who has recruited for companies in both hemispheres. The two Ians will reflect on lessons from their careers which took them throughout the region.
- As Asian markets become increasingly important to the world pharma industry, major new staffing challenges are emerging.
- Emerging markets mean the emergence of an ever-widening talent pool on which the industry can draw.
- The career paths of classic "western" expatriate executives are being challenged by these new reservoirs of cheap, increasingly well-educated, and innovative local executives. As cost pressures grow on global companies, the use of western executives will be increasingly scrutinised. What kinds of career paths in Asia are best suited for such managers who are on a global career track?
- To what extent are global or pan-Asian career paths emerging for Asian executive talent?
- How are Asian companies handling the staffing of their international operations? What roles do they tend to assign western executives? Can westerners develop genuinely international career paths within Asian-owned pharma companies?
Nick Stephens
Nick has been a Director of RSA since 1986 and joined the business full-time in 1995. In 2000 he became Managing Director of RSA Consulting Ltd - the RSA "group" company. Following a major restructure in September 2005 Nick took up a new position as CEO. In this role he has led the transformation of RSA into a truly global company launching new wholly-owned businesses in Singapore, London, New Jersey, France, Germany and Switzerland and a JV in China. Nick studied Law at the University of East Anglia and Business at Cranfield and has broad commercial experience gained through various roles in metals trading, healthcare, pharmaceuticals and the British National Health Service as well as from his time at RSA.
Ian Boulton
Until six months ago, Ian was Director, Global Commercial Strategy, Diseases of the Developing World, GlaxoSmithKline.
Ian Price
Pharmaceutical/Healthcare Senior Executive with career spanning three US Multinational companies, mainly in line management, originating from a Sales/Marketing background and entry to the industry. Early marketing career in pharmaceuticals (GD Searle) and pharmaceuticals/ clinical devices (Abbott). Latter career (Schering-Plough) in pharmaceuticals gaining multi-country line experience, both, in a General Management/CEO role (Norway, Portugal, Australia/New Zealand) and later as Regional Vice President for the Far East/ Australasia/South Africa region. Later position, Vice President – European Business Support (two and half years) enhancing European and International groups in Business Development ; late phase new product search/licensing, mid-cap Pharma company acquisition screening [via Merchant Banks], review of Biotech company acquisition/license opportunities and projects in European multiple-site manufacturing rationalization and European salesforce additional resourcing.